Solventum Q2 Profit Rises, Lifts Full-Year Sales Outlook
SOLV sits 45% above its 52-week low of $62.38.
Summary
Solventum delivered a modest Q2 beat with GAAP EPS of $0.53 vs. $0.51 a year ago, while adjusted EPS came in at $2.55. Revenue grew 2.2% to $2.209 billion. More importantly, management raised its full-year organic sales growth guidance to +2.5% to +3.0% and set EPS guidance at $7.10 to $7.20. This follows a Q1 marked by sharply lower GAAP net income and negative operating cash flow, making the Q2 rebound and raised outlook a positive signal. The stock is trading near its 52-week high, so the market may have priced in some improvement, but the guidance lift could still drive further upside.
At the time of this announcement, SOLV was trading at $90.48 on NYSE in the Life Sciences sector, with a market capitalization of approximately $15.1B. The 52-week trading range was $62.38 to $88.65. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: dpa-AFX.